After CAR-T: how long a patient cannot drive, how near the center to stay, and who drives to clinic visits

How long can a patient not drive after CAR-T?

For five of the six products in the FDA’s notice, the label says to avoid driving for at least two weeks after infusion, and for Abecma it says at least one week. The same labels tell the treatment center to instruct the patient to stay within proximity of a healthcare facility for the same length of time. The FDA’s June 26, 2025 safety communication eliminated the risk program (REMS) for the six products. It described the label change as monitoring for at least two weeks, with daily monitoring for at least one week, staying near a healthcare facility for at least two weeks, and avoiding driving for two weeks. Abecma’s label, revised in November 2025, now says one week for both.

Each label carries its own revision date: Yescarta in August 2026, Tecartus in June 2026, Breyanzi in February 2026, Carvykti in October 2025, Kymriah in June 2025, and Abecma, the one that says a week, in November 2025.

A newer CAR-T product that the FDA’s notice does not list follows its own label. The treating team can also add to these periods, so the center’s instructions are the ones to book around. With the REMS gone, hospitals no longer need special certification to give these products, and the FDA said it expects the change to improve access, particularly for patients who live in rural areas. Infusion days and chemotherapy rides in general are in the cancer treatment transportation guide; this page covers what is specific to CAR-T.

How near the center does the patient have to stay?

The labels give no distance. They say “within proximity of a healthcare facility” and leave the distance to the treating center. Ask the center three things when the infusion date is set: how far from the center the patient may stay, whether the patient may stay at home, and the address of the lodging if not. The daily rides run from that address, so it has to be given to the ride company before the first trip.

The label also sets the first-week routine. The patient is monitored at least daily for seven days after infusion, and the labels do not say whether that happens in a hospital bed or at a daily outpatient visit. The Medication Guides say a patient may be hospitalized for side effects and is discharged when the side effects are under control. A patient who is not admitted generally has to get to the center for that daily check, so plan a trip for each day of that first week unless the center says otherwise.

One product’s label shows how the whole course of rides can run. Yescarta’s label describes blood collection for manufacturing, then three days of chemotherapy given on the fifth, fourth and third days before infusion, then an infusion that usually takes less than 30 minutes, then daily monitoring for at least seven days, then at least two weeks nearby, with periodic blood tests after that. Treat that as one example: other products, indications and centers set different visit counts.

Who drives the patient to clinic visits?

The patient does not drive, so someone else does, and the FDA labels do not say who. The labels tell the patient to avoid driving and to stay near a facility. None of the six labels sets a caregiver requirement. The labels leave caregiver rules to the treating center, so the family or the center’s social worker should ask what it requires and relay that to the ride company.

For a ride company, that sorts the daily runs into three patterns:

• Family drives. The ride company is the backup for days the family driver cannot. Ask the broker or plan how short-notice requests are handled before the day you need one.
• Ride company drives every day. Book the first week as daily trips from the lodging, with the arrival time the center gives. Visits can run long, so the return should be a will-call.
• A caregiver rides along. Book the caregiver as an escort so the seat is held.

After the first week, the number of visits depends on the center, and the label’s instruction to stay nearby runs through week two (week one for Abecma). Ask the center for the visit dates in one list, and book them as one series where the plan allows. The cancer treatment guide covers how infusion days run and why a return should wait on the clinic.

What should a driver do if a CAR-T rider is confused or has a fever?

Report it at once and call 911 when the rider has trouble breathing, is confused, has a seizure or cannot be woken. These are the warning signs Yescarta’s Medication Guide gives for cytokine release syndrome and neurologic problems, and the other products’ guides give similar lists. The guide tells patients to call or see their healthcare provider, or get emergency help right away, for any of these:

• Fever of 100.4°F (38°C) or higher, or chills and shaking chills
• Difficulty breathing
• Confusion
• Dizziness or lightheadedness
• Severe nausea, vomiting or diarrhea
• A fast or irregular heartbeat
• Severe fatigue or weakness

A driver is not a clinician and does not decide which of these matters. The driver’s part is to notice, stay with the rider, tell the escort and dispatch, and call 911 when the rider is in danger. The guides tell the rider to call or see their healthcare provider, and some products come with a patient wallet card the patient is told to show to providers. The Breyanzi and Abecma Medication Guides name one.

The timing in Yescarta’s label shows why the first week matters. The median onset of cytokine release syndrome was 2 days after infusion in one large B-cell lymphoma study, and 87% of affected large B-cell lymphoma patients who had neurologic toxicity had it within seven days. The label also reports that 98% of neurologic toxicities in those patients came within eight weeks, and that late-onset encephalopathy has occurred. A rider who is confused on a visit in week three is still a call to the center. The guides to medical emergencies on board and transporting riders with dementia cover handling a confused passenger.

Do CAR-T riders need infection precautions?

Ask the center what it wants for each rider, because these patients have had lymphodepleting chemotherapy and the labels warn of serious infections and low blood counts. Yescarta’s label reports infections of any grade in 45% of treated patients with non-Hodgkin lymphoma, grade 3 or higher infections in 17%, and febrile neutropenia in 36%. It also lists prolonged cytopenias, meaning low blood counts that persist, among its warnings.

For a ride company, the center’s instruction decides the details. Ask whether the rider should wear a mask in the van, whether shared trips are acceptable, and whether the van needs special handling after the trip. Single-rider trips are the simplest way to keep exposure down. The infection control guide covers cleaning, and the cancer guide covers riders with low counts, so this page does not repeat either.

What changes after an allogeneic stem cell transplant?

The time near the center is much longer, about 100 days instead of two weeks. The National Cancer Institute says a patient with no problems can go home 100 days after receiving the donor stem cells, that a patient who does not live nearby needs a hotel or apartment when out of the hospital, and that the patient stays closely followed by a doctor with transplant experience. It adds that acute graft-versus-host disease occurs within the first 3 months after transplant. NMDP says the process from the start of chemotherapy to hospital discharge can last weeks to months, followed by many months of recovery near the transplant center and at home.

A patient who has a transplant therefore needs a longer series of rides, and the lodging and visit rules need to be set with the center. The guide to transportation for transplant patients covers organ transplants and the call for a donor organ, which differ.

Who pays for the lodging and the rides?

Medicaid can pay for rides, meals and lodging to a covered service when the patient has no other way to get there, and the state decides how. CMS’s transportation guide says the transportation a state must provide includes related travel expenses that are necessary, such as meals, lodging and a transportation attendant, and that the attendant’s cost can include transportation, meals, lodging and salary when the attendant is not a family member. A center in another county or state may need approval before the trip. The guides to Medicaid lodging and meals for medical travel and out-of-county Medicaid transportation cover how to ask.

Daily clinic runs in HealthRide

HealthRide can hold the first week’s daily trips as a series, so the dispatcher enters the pattern once and each day’s ride appears on the board. A return from the center can wait as a flexible trip that goes live when the clinic is done, which fits a visit that can run long. A caregiver is added to the trip as an escort, and the rider’s family gets a text link to follow the van. See recurring trips for how a series is set up.